Soy foods have become popular in Western countries through the suggestion that they have health benefits, including protection against coronary heart disease \[[@B1]\], breast and prostate cancer \[[@B4]\], osteoporosis \[[@B7]\], and alleviation of hot flushes \[[@B8]\]. This has led to the development of isoflavone supplements and the fortification of foods with soy constituents \[[@B9]\]. There are concerns that soy may adversely affect thyroid function in susceptible individuals \[[@B11]\], and *in vitro* studies have demonstrated that isoflavones inhibit thyroid peroxidase, an enzyme involved in the synthesis of triiodothyronine (T3) and thyroxine (T4) \[[@B13]\].

The two main components of soy thought to be responsible for most of the proposed health benefits of soy are soy protein and the soy isoflavones, of which genistein is more biologically potent that daidzein and glycitein. It is unclear which component of soy (the protein, the isoflavones, or an interaction between the two) may have an effect on thyroid function \[[@B12]\]. It has not previously been possible to determine the relative effective contribution of each component, as there are no studies either *in vitro* or *in vivo* with an isoflavone-free soy preparation.

Studies have shown that soy protein with isoflavones has an adverse effect on thyroid function \[[@B16]\], and another study in subclinical hypothyroidism was associated with a threefold increased risk of developing overt hypothyroidism \[[@B15]\]. These studies have also highlighted the positive effect of soy on cardiovascular risk, reducing insulin resistance, highly sensitive C-reactive protein (hsCRP), and blood pressure. However, it is not known whether the effects observed were due to isoflavones alone or due to the isoflavones in combination with the soy protein, although a study performed with isoflavones alone showed no beneficial effects, whereas the same isoflavone preparation with soy protein was effective in improving glycemic control and reducing cardiovascular risk parameters \[[@B18]\], suggesting that soy protein alone may have inherent activity. Therefore, this double-blind, crossover trial was undertaken to determine the effect of soy protein alone on thyroid parameters in patients with compromised thyroid function (subclinical hypothyroidism), with a secondary outcome to evaluate cardiovascular risk markers, by comparing 30 g isolated soy (isoflavone-free) protein (SP) with 30 g casein protein (CP).

1. Subjects and Methods {#s5}
=======================

Eighty patients, 27 males and 53 female subjects with subclinical hypothyroidism (age range, 20 to 81 years) \[thyrotropin (TSH) value between 5 and 15 mU/L; normal range 0.5 to 4.7 mU/L, with a normal free T4 (fT4)\], were recruited by identification from the routine biochemical testing performed at Hull Royal Infirmary, United Kingdom, over a 12-month period. The screening thyroid function tests were done 4 to 8 weeks after the initial biochemical testing ([Table 1](#T1){ref-type="table"}). Exclusion criteria included patients taking thyroxine or drugs that may interfere with thyroid function, antihypertensive agents, insulin-sensitizing agents, lipid-lowering medications, as well as antibiotic use within the last 6 months. Women who were contemplating pregnancy were also excluded. Subjects were instructed, at randomization and then at each subsequent visit, to maintain their level of physical activity throughout the study and avoid food products containing soy, alcohol, vitamin or mineral supplementation, and over-the-counter medications. Ethics approval was obtained from Hull and East Yorkshire Ethics Committee.

###### 

**Thyroid Function Tests at the Start and 2 Months After Supplementation**

  **Soy Protein (SP)**   **Casein Protein (CP)**   **Postactive--Postplacebo**                                               
  ---------------------- ------------------------- ----------------------------- ------ -------------- -------------- ------ ------
  fT3                    4.44 ± 0.51               4.37 ± 0.46                   0.32   4.40 ± 0.58    4.43 ± 0.42    0.70   0.88
  fT4                    12.60 ± 1.26              11.06 ± 1.63                  0.08   12.11 ± 1.40   11.93 ± 1.77   0.48   0.32
  TSH                    5.70 ± 1.01               5.86 ± 2.08                   0.56   5.93 ± 2.16    5.71 ± 2.16    0.12   0.54

fT3, pmol/L; fT4, pmol/L; TSH, mU/L (mean ± standard deviation).

Abbreviation: fT3, free triiodothyronine.

Forty patients were initiated after randomization with a cereal bar containing 30 g isolated SP and 40 patients with a cereal bar containing 30 g CP per day for 8 weeks (first phase). After an 8-week washout period, the participants received the alternative supplementation for 8 weeks (second phase). An eight-week time period was chosen for each arm as this was the minimum time of exposure that might have been expected to affect thyroid function, given that the half-life of thyroxine is \~7 days. Compliance was calculated by counting the returned bars.

Soy was supplied by Solbar Industries (Ashdod, Israel). Isoflavones were removed by serial alcohol washing (Dishman, Ahmedabad, India) to a level ˂300 parts per billion (assayed by FERA, Sand Hutton, United Kingdom). Casein bars were prepared from a single batch, and each bar contained the same amount of protein. Soy and casein bars were prepared by Halo Foods (Swindon, United Kingdom), and the study product was then randomized by Essential Nutrition (Brough, United Kingdom) using a computer-generated block randomization list.

The primary outcome of the study was a change in serum-free thyroxine, whereas secondary outcome measures were blood pressure, homeostasis model assessment of insulin resistance (HOMA-IR), lipids, and hsCRP. Overt hypothyroidism was defined as a combination of TSH \>4.7 mU/L and fT4 \<9 pmol/L. A flow chart of patients through the study is given in [Fig. 1](#F1){ref-type="fig"}.

![Flow chart describing the progress of patients through the trial.](js-01-423-f1){#F1}

A. Study Measurements {#s6}
---------------------

The weight and blood pressure of participants were measured, and blood samples were collected at the beginning and end of each phase, following an overnight fast. Blood pressure was measured after the patients had been seated quietly for at least 5 minutes with the right arm supported at heart level. Blood pressure measurements were performed using an automated device (NPB-3900; Nellcor Puritan Bennett, Pleasanton, CA) during each study visit. Two readings were obtained at the beginning of each visit at least 1 minute apart, and the mean value was taken. Fasting venous blood samples were collected and separated by centrifugation at 2000*g* for 15 minutes at 4°C, and the aliquots were stored at −80°C within 1 hour of collection. Plasma glucose was measured using a Synchron LX20 analyzer (Beckman-Coulter, High Wycombe, United Kingdom), and serum insulin was assayed using a competitive chemiluminescent immunoassay performed using the DPC Immulite 2000 analyzer (Euro/DPC, Llanberis, United Kingdom). The coefficient of variation of this method was 8%, calculated using duplicate study samples. The analytical sensitivity was 2 µU/mL. Insulin resistance was calculated using HOMA-IR (insulin × glucose)/22.5) \[[@B19]\]. Total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol levels were measured enzymatically using a Synchron LX20 analyzer (Beckman-Coulter). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation. All thyroid assays were performed on an Abbott Architect i4000 immunoassay analyzer (Abbott Diagnostics Division, Maidenhead, United Kingdom). The reference range for TSH was 0.5 to 4.7 mU/L; fT4, 9 to 24 pmol/L; and free T3, 2.5 to 5.3 pmol/L. Urinary iodine measurements in 24-hour urine collections were undertaken by inductively coupled plasma--mass spectrometry to monitor for iodine repletion, and plasma phytoestrogen measurement was undertaken by liquid chromatography--tandem mass spectrometry (HFL Sport Science Laboratory, Cambridge, United Kingdom).

B. Statistical Analysis {#s7}
-----------------------

For a significant reduction in fT4, a sample size of 40 patients in a crossover design was calculated giving 80% power to detect a mean decrease of 0.4 pmol/L fT4, with a two-sided α error of 0.05 \[[@B18]\]. Given the high dropout rate with this type of study, it was elected to recruit 80 patients and accept a dropout rate of 50%. Mean percentage changes obtained at the end of supplementation with 30 g SP were compared with the results at the end of placebo CP using the paired Student *t* test for biochemical data and Wilcoxon's signed--rank test for clinical observations. Baseline parameters were not compared statistically because this was a randomized controlled study \[[@B20]\].

Wilcoxon's signed--rank test was applied to biochemical data that violated the assumptions of normality when tested using the Kolmogorov--Smirnov test. The period and the carryover effect that may have occurred from the crossover design were also tested using the appropriate Student *t* test. Intention to treat analysis was done. Statistical correction for multiple testing since was not done because it can severely reduce power to detect important effects due to the fact that the general null hypothesis (that all the null hypotheses are true) is not of interest and there is a high probability of type II errors \[[@B22]\].

Statistical analysis was performed using SPSS for windows version 22.0. An arbitrary level of 5% statistical significance (two-tailed) was assumed. The data are reported as mean ± standard deviation.

2. Results {#s8}
==========

Mean age of patients was 55.1 ± 14.2 years. The mean body mass index (BMI) of patients was 28.8 ± 5.9 kg/m^2^; mean systolic blood pressure was 134.2 ± 22.2 mm Hg; and mean diastolic blood pressure was 81.5 ± 14.2 mm Hg. Thyroid peroxidase antibodies were positive (\>75 U/mL) in 27 (33.7%) patients. Compliance was 98% in both groups. Of the 27 male and 53 female subjects with subclinical hypothyroidism that started the study, 16 males and 26 females completed.

The mean TSH, free T3, and fT4 levels remained unchanged before and after supplementation with either soy protein or CP. No patient developed overt hypothyroidism during the study.

Weight and BMI were unchanged after either SP or CP supplementation. There were no differences in mean systolic or diastolic blood pressures between the groups. There was a significant decrease in mean glucose (*P* \< 0.01) that reflected in a decrease in HOMA-IR (*P* = 0.05) in patients who received SP supplementation compared with CP ([Table 2](#T2){ref-type="table"}).

###### 

**Subjects' Characteristics and Effects on Cardiovascular Risk at the Start of the Trial and 2 Months After Supplementation**

  **Soy Protein (SP)**   **Casein Protein (CP)**   **Postactive--Postplacebo**                                                 
  ---------------------- ------------------------- ----------------------------- -------- -------------- -------------- ------ --------
  Weight                 84.0 ± 20.4               84.4 ± 20.4                   0.09     84.4 ± 20.3    84.8 ± 20.5    0.1    0.99
  BMI                    29.0 ± 5.6                29.1 ± 5.7                    0.07     29.3 ± 5.6     29.4 ± 6.1     0.07   0.91
  SBP                    131.4 ± 18.2              130.3 ± 17.9                  0.5      133.5 ± 23.4   129.9 ± 17.8   0.1    0.40
  DBP                    81.3 ± 13.9               78.6 ± 13.9                   0.2      82.1 ± 13.1    77.4 ± 11.6    0.01   0.47
  Glucose                6.2 ± 0.9                 4.7 ± 0.6                     \<0.01   5.4 ± 1.3      5.5 ± 1.4      0.07   \<0.01
  Insulin                12.4 ± 9.9                14.9 ± 13.6                   0.03     13.4 ± 10.3    14.3 ± 10.5    0.3    0.23
  HOMA-IR                3.6 ± 3.0                 3.3 ± 3.0                     0.2      3.5 ± 3.4      3.8 ± 3.4      0.2    0.05
  TC                     5.3 ± 1.2                 4.4 ± 0.9                     \<0.01   5.3 ± 1.1      5.4 ± 1.2      0.2    \<0.01
  LDL                    3.3 ± 1.1                 3.2 ± 1.1                     0.4      3.2 ± 1.2      3.3 ± 1.0      0.5    0.26
  HDL                    1.4 ± 0.4                 1.5 ± 1.6                     0.5      1.3 ± 0.4      1.3 ± 0.4      0.7    0.54
  TG                     2.6 ± 0.9                 0.9 ± 0.5                     \<0.01   1.6 ± 0.8      1.7 ± 0.9      0.3    \<0.01
  hsCRP                  3.4 ± 2.6                 0.8 ± 0.7                     \<0.01   2.4 ± 2.5      2.6 ± 2.8      0.5    \<0.01

BMI, kg/m^2^; SBP, mm Hg; DBP, mm Hg; glucose, plasma glucose, mmol/L; insulin, µIU/mL; TC, mmol/L; TG, mmol/L; LDL, mmol/L; HDL, mmol/L; hsCRP, mg/L. To convert values for glucose to milligrams per decilitre, divide by 0.056. To convert values for insulin to picomoles per liter, multiply by 6. To convert values for cholesterol to milligrams per decilitre, divide by 0.0259. To convert values for triglycerides to milligrams per decilitre, divide by 0.0113.

Abbreviations: DBP, diastolic blood pressure, SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.

There was a decrease in the total cholesterol and triglycerides (*P* \< 0.01) in patients who received SP supplementation compared with CP between groups, but HDL cholesterol levels did not differ ([Table 2](#T2){ref-type="table"}). There was a reduction in LDL of \~3% with soy protein and an increase in LDL of \~3% with CP; this was not found to be statistically significant ([Table 2](#T2){ref-type="table"}).

There was a significant reduction in mean hsCRP (*P* \< 0.01) in patients who received SP that was not seen with CP ([Table 2](#T2){ref-type="table"}).

The calculated 10-year cardiovascular risk using the Framingham equation was 13.3% for both SP and CP that fell to 11.2% following SP, a significant 2.1% absolute and a 10% relative fall (*P* \< 0.05) between groups.

3. Discussion {#s9}
=============

Studies on soy with isoflavones have shown a significant effect on both T4 and TSH levels \[[@B16]\], and these data using an isolated soy protein, isoflavone-free preparation confirm that SP is not responsible for those changes that are therefore likely to be due to the intrinsic isoflavone component of soy. CP has been shown previously to have no effect on thyroid function in postmenopausal women \[[@B23]\].

A significant improvement in plasma glucose and a fall in HOMA after SP were observed, in accordance with a meta-analysis of randomized trials \[[@B24]\], and more recent soy isoflavone studies \[[@B16]\] showed a significant decrease in plasma glucose that may in part be due to the SP alone, as shown in this work.

Insulin resistance (HOMA-IR) significantly improved in patients supplemented with SP compared with CP, which was in accordance with studies that have shown isoflavones in soy protein improve insulin resistance \[[@B18]\]; however, this effect appears to be lost when isoflavones are given alone (without soy protein) \[[@B26]\].

There was a significant improvement in total cholesterol and triglyceride values after soy protein supplementation, although LDL and HDL were not altered. Some previous studies have suggested that the lipid-lowering effects are mainly due to the isoflavone content, but this study showed that soy protein alone most likely contributes to the lipid-lowering effects reported. However, the observed effects on lipid lowering have not been consistent; some studies have shown an improvement with the soy preparation \[[@B29]\], whereas others have shown no benefit on total cholesterol, LDL cholesterol, and triglycerides \[[@B33]\]; likewise, isoflavones alone have shown no lipid benefit \[[@B36]\]. These differences reported by others may be due in part to the differing preparations used.

There was no improvement seen in BMI and weight, but the marker of inflammation, hsCRP, was reduced significantly after soy protein supplementation. In accordance with the lipid data, previous studies have shown an improvement in hsCRP in some \[[@B38]\] but not all studies \[[@B40]\] that most likely reflects the differing soy preparations and study conditions used. Our study suggests that isolated soy protein has anti-inflammatory effects.

Although there was no difference in the protein composition between soy with and without isoflavones following serial alcohol washing and digestion of protein that should have not differed following ingestion, nonetheless the serial alcohol washing could have altered the tertiary structure of the protein and removed other components besides isoflavones.

The study limitations include the increased dropout seen that was mitigated by appropriate powering of the study and its crossover design. The number of participants who completed the study was similar to other studies \[[@B15]\]. Secondly, the ratio of male and female participants who completed the study did not alter, thus alleviating the effect of different response of males and females to soy isoflavones reported previously \[[@B43]\]. Although there was no difference in the protein composition between soy with and without isoflavones following serial alcohol washing, and digestion of protein should have not differed following ingestion, nonetheless the serial alcohol washing could have altered the tertiary structure of the protein and removed other components besides isoflavones.

In conclusion, isolated SP had no effect on thyroid function in patients with subclinical hypothyroidism and resulted in a significant reduction in fasting glucose, insulin resistance, total cholesterol, triglycerides, and hsCRP compared with CP.

Abbreviations: BMIbody mass indexCPcasein proteinfT4free T4HDLhigh-density lipoproteinHOMA-IRhomeostasis model assessment of insulin resistancehsCRPhighly sensitive C-reactive proteinLDLlow-density lipoproteinSPsoy (isoflavone-free) proteinT3triiodothyronineT4thyroxineTSHthyrotropin.
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